News Lundbeck retreats from dozens of markets, slashing staff Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partners.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.